# Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

> **NCT07642635** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy (DMD)

## Interventions

- **DRUG:** Semaglutide (Rybelsus®)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07642635
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2030-09
- **Final completion:** 2030-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07642635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07642635, "Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07642635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*